Key Words: gallium-67; lymphoma

öeveral papers have recently been published on the use of 67Ga scintigraphy in lymphoma—with the emphasis on its value after treatment (1-7). These articles provide further evidence of the utility of 67Ga to monitor patients (8-14). The ability of 67Ga scintigraphy to detect recurrence early during clinical remission, when the tumor load is small and other tests are not sensitive enough for early detection, has been described (2). Recently, we suggested the potential use of 67Ga scintigraphy to evaluate the rapidity of response to treatment, if there is the possibility to achieve better overall response by changing therapy in patients who do not respond rapidly to first line chemotherapy (6). While 67Ga scintigraphy has a clearly established role in determining whether a lymphoma patient has responded to treatment and in the early diagnosis of a recu